Invention Grant
- Patent Title: Treatment of cancer using a CD123 chimeric antigen receptor
-
Application No.: US14830392Application Date: 2015-08-19
-
Publication No.: US09815901B2Publication Date: 2017-11-14
- Inventor: Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
- Applicant: Jennifer Brogdon , Saar Gill , David Glass , Saad Kenderian , Andreas Loew , Joan Mannick , Michael C. Milone , Leon Murphy , David L. Porter , Marco Ruella , Yongqiang Wang , Qilong Wu , Jiquan Zhang
- Applicant Address: CH Basel US PA Philadelphia
- Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee: Novartis AG,The Trustees of the University of Pennsylvania
- Current Assignee Address: CH Basel US PA Philadelphia
- Agency: Lando & Anastasi, LLP
- Priority: WOPCT/CN2014/084696 20140819; WOPCT/CN2014/090508 20141106
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C12N5/078 ; C12N5/0783 ; A61K39/00 ; C07K16/24
Abstract:
The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.
Public/Granted literature
- US20160068601A1 TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR Public/Granted day:2016-03-10
Information query
